Intarcia grants right to ITCA 650 in ex-U.S./Japan territories; Intarcia retains full control in U.S. and plans another partner in Japan. Deal payments may total up to more than $1B to Intarcia.
Our highly competitive six-month search concluded with what is likely the largest ex-U.S. partnership in biotech history. Our new partner, Servier, is an extraordinarily well suited strategic match for us outside the United States with a strong presence in 140 countries, deep experience in diabetes, and a shared vision for disruptive innovation.
Two of the FREEDOM Phase 3 clinical trials are now successfully completed: FREEDOM-1 and the FREEDOM-1 HBL studies both met all their clinical endpoints. There are two remaining studies in the overall program: FREEDOM-2 and the FREEDOM-CVO Safety Study.
Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia
What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"